Myelodysplastic Syndromes |
Services dHematologie Clinique et Biologique, Hôpital Avicenne, Université Paris-XIII, APHP, Bobigny, France
Correspondence: Virginie Eclache, Services dhematologie clinique & biologique, Hôpital Avicenne, Universite Paris-XIII, APHP, 125, rue de Stalingrad, 93000 Bobigny, France E-mail: virginie.eclache{at}avc.ap-hop-paris.fr
Lenalidomide is a very active drug in myelodysplastic syndrome with del (5q). We report such a patient treated with this drug who developed unusual complex cytogenetic abnormalities, which were elucidated by multi-FISH and FISH analysis as jumping translocations involving the long arm of chromosome 5, that resulted in an increase of 5q copies. This unusual findings is discussed in the context of resistance to lenalidomide observed in this patient.
Key words: lenalidomide, myelodysplastic syndromes, del(5q) MDS, transfusion-dependent, case study.
This article has been cited by other articles:
![]() |
M. Jadersten, L. Saft, A. Pellagatti, G. Gohring, J. S. Wainscoat, J. Boultwood, A. Porwit, B. Schlegelberger, and E. Hellstrom-Lindberg Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression Haematologica, December 1, 2009; 94(12): 1762 - 1766. [Abstract] [Full Text] [PDF] |
||||